Tyenne 400 mg (Tocilizumab SOLUTION) 400 MG

TYENNE 400 MG is an intravenous solution containing Tocilizumab, used for managing inflammatory conditions. This medication is designed to help reduce inflammation and improve symptoms.

Strength

400 MG

Manufacturer / TM Owner

FRESENIUS KABI CANADA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TYENNE 400 MG is primarily used to manage inflammatory conditions. It works by targeting specific pathways in the body to reduce inflammation. This solution is often prescribed for conditions where inflammation plays a key role, helping to alleviate symptoms and improve quality of life.

Side Effects

TYENNE 400 MG may cause various effects, including but not limited to, injection site reactions, headaches, and fatigue. Some individuals might experience changes in blood pressure or liver function. It's important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

TYENNE 400 MG should be handled with care, following the instructions provided by a healthcare professional. It is crucial to inform your healthcare provider about any existing medical conditions or allergies before starting this medication. Proper storage and administration are essential to ensure safety and effectiveness.

Avoid Interactions

TYENNE 400 MG may interact with other medications, including those that affect the immune system or liver function. It's important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements might also influence the effects of this solution.

Frequently Asked Questions

TYENNE 400 MG is used to manage inflammatory conditions by reducing inflammation in the body.

TYENNE 400 MG is administered intravenously, typically in a clinical setting under the supervision of a healthcare professional.

Common effects may include injection site reactions, headaches, and fatigue. Monitoring for any unusual symptoms is recommended.

TYENNE 400 MG may interact with other medications, so it's important to discuss all current medications with a healthcare provider.

Precautions include informing your healthcare provider about existing medical conditions or allergies and following proper storage and administration guidelines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.